The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: The role of inflammation

C-Reactive Protein, Fatal and Nonfatal Coronary Artery Disease, Stroke, and Peripheral Artery Disease in the Prospective EPIC-Norfolk Cohort Study

“…This concept is supported by studies reporting that CRP as well as CRPcomplement complexes accumulate in infarcted human myocardium. 19,33 CRP bound to ischemic cardiomyocytes has been shown to recruit complement factor 1a and thereby activate the complement system, 20 and injection of human CRP into rats after ligation of the coronary artery enhanced infarct size by ≈40%. This concept is further corroborated by the observation that in vivo complement depletion markedly reduced infarct size, even when initiated up to 2 hours after coronary ligation.…”

“…16,17 Both in vitro and in vivo data indicate that not only inflammation in general but also CRP itself can aggravate myocardial infarction promoting more severe cardiovascular events. [18][19][20][21] We therefore hypothesized that CRP is more strongly associated with fatal compared with nonfatal CAD events, strokes, and PAD events in the general population. We tested this hypothesis in the EPIC-Norfolk prospective population study.…”

Baseline levels of C-reactive protein and no-reflow after primary percutaneous coronary intervention: When the time does matter

“…We thank Dr. Celik et al [1] for their interest in our study on the relation between serum levels of C-reactive protein (CRP) and coronary no-reflow after primary PCI [2]. In their letter, the authors report that in a previous study, at variance with our data, they noticed a significant relation between CRP levels (and, therefore, inflammation) and no-reflow in this kind of patients [3].…”

The association of serum procalcitonin level with the no-reflow phenomenon after a primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction

“…Akpek et al [27] reported that the neutrophil to lymphocyte ratio and CRP had a significant and positive correlation with no-reflow in patients with STEMI after PPCI. Also, Celik et al [28] found that CRP-mediated complement activation and neutrophil plugging may be the factors contributing toward the development of no-reflow in AMI patients treated with PPCI. In this respect, we also examined the correlation between hs-CRP and PCT levels and found a positive correlation between serum PCT and hs-CRP levels in the study population.…”